Novo Nordisk AS (HAM:NOVA) FFO per Share


HAM:NOVA Novo Nordisk AS HAM:NOVA
83 GF Score
Price €42.74
GF Value €120.61
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO per Share?

FFO per Share only applies to REITs.

HAM:NOVA
83GF Score
Novo Nordisk AS HAM:NOVA
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €42.74 is trading 64.6% below its estimated GF Value™ of €120.61. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOVA:

  • FFO per Share:
  • GF Value™: €120.61 vs. price of €42.74 (64.6% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score

Get the complete analysis for HAM:NOVA

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.74
Price
€120.61
GF Value